Dompé is a privately owned biopharmaceutical company with 130 years of experience. Headquartered in Milan, we operate in Boston, San Francisco, and Shanghai. Dompé is committed to medical and scientific advancement, through our own research and open innovation ecosystem.
Prescription drugs and OTC products, dietary supplements, medical devices and cosmetics
Treatment of rare diseases with no approved treatment
Diabetes, Opthalmology, and conditions with high unmet need
Revenues in euro (2020)
Europe, United States, China
Packages manufactured in 2020
Production lines (7 synthesis, 1 biotech)
Synthesis and biotech
EMA (European Medicines Agency), Europe
FDA (Food and Drug Administration), United States
NMPA (National Medical Products Administration), China
We have developed the first application of rhNGF (recombinant human Nerve Growth Factor) as a commercial therapy. Dompé's
rhNGF is the first and only pharmacologic treatment specifically indicated for Neurotrophic Keratitis, approved by the FDA and EMA.
Year of marketing authorization granted by the EMA in Europe and granted breakthrough, fast track and priority review designations by FDA in the US
Chinese National Medical Products Administration (NMPA) inclusion among the 40 clinically needed drugs overseas
Expected NMPA marketking authorization
Dompé farmaceutici is established in 1940, stemming from a pharmacological roots dating back to the Nineteenth Century
Gian Antonio Dompé devotes himself to studying chemical-pharmaceutical sciences and eventually becomes a science savant.
Onorato Dompé, Gian Antonio’s son, establishes the Dompé-Adami laboratory in Milan.
Onorato Dompé establishes the first pharmaceutical production plant in Milan.
Franco Dompé, Onorato’s son, founds Dompé farmaceutici in Milan.